PL234887B1 - Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej - Google Patents
Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej Download PDFInfo
- Publication number
- PL234887B1 PL234887B1 PL401934A PL40193412A PL234887B1 PL 234887 B1 PL234887 B1 PL 234887B1 PL 401934 A PL401934 A PL 401934A PL 40193412 A PL40193412 A PL 40193412A PL 234887 B1 PL234887 B1 PL 234887B1
- Authority
- PL
- Poland
- Prior art keywords
- ppi
- mal
- cells
- iii
- dendrimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401934A PL234887B1 (pl) | 2012-12-06 | 2012-12-06 | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
| KR1020157018092A KR20150099539A (ko) | 2012-12-06 | 2013-12-03 | 말토트리오즈-코팅된 제 4 세대 폴리프로필렌이민 덴르리머 PPI-G4-DS-Mal-III의 적용 |
| PCT/PL2013/000154 WO2014088434A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii |
| CA2896673A CA2896673A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii |
| JP2015546418A JP2016501260A (ja) | 2012-12-06 | 2013-12-03 | マルトトリオースで被覆された第四世代ポリプロピレンイミンデンドリマーPPI−G4−DS−Mal−IIIの使用 |
| US14/650,458 US20150320692A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii |
| EP13821003.4A EP2928478A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii |
| AU2013356792A AU2013356792A1 (en) | 2012-12-06 | 2013-12-03 | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III |
| IL239143A IL239143A0 (en) | 2012-12-06 | 2015-06-02 | Application of fourth-generation polypropyleneamine dendrimer ppi–g4–ds–mal–iii coated with maltodextrin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL401934A PL234887B1 (pl) | 2012-12-06 | 2012-12-06 | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL401934A1 PL401934A1 (pl) | 2014-06-09 |
| PL234887B1 true PL234887B1 (pl) | 2020-04-30 |
Family
ID=49955471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL401934A PL234887B1 (pl) | 2012-12-06 | 2012-12-06 | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150320692A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2928478A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2016501260A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20150099539A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013356792A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2896673A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL239143A0 (cg-RX-API-DMAC10.html) |
| PL (1) | PL234887B1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014088434A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL234888B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090208580A1 (en) * | 2005-09-19 | 2009-08-20 | Regents Of The University Of Michigan | Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles |
| US20110177602A1 (en) * | 2007-06-27 | 2011-07-21 | Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG | Composite Structure |
| PL234888B1 (pl) * | 2012-12-06 | 2020-04-30 | Univ Lodzki | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej |
-
2012
- 2012-12-06 PL PL401934A patent/PL234887B1/pl unknown
-
2013
- 2013-12-03 AU AU2013356792A patent/AU2013356792A1/en not_active Abandoned
- 2013-12-03 KR KR1020157018092A patent/KR20150099539A/ko not_active Withdrawn
- 2013-12-03 WO PCT/PL2013/000154 patent/WO2014088434A1/en not_active Ceased
- 2013-12-03 US US14/650,458 patent/US20150320692A1/en not_active Abandoned
- 2013-12-03 EP EP13821003.4A patent/EP2928478A1/en not_active Withdrawn
- 2013-12-03 CA CA2896673A patent/CA2896673A1/en not_active Abandoned
- 2013-12-03 JP JP2015546418A patent/JP2016501260A/ja active Pending
-
2015
- 2015-06-02 IL IL239143A patent/IL239143A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016501260A (ja) | 2016-01-18 |
| EP2928478A1 (en) | 2015-10-14 |
| US20150320692A1 (en) | 2015-11-12 |
| KR20150099539A (ko) | 2015-08-31 |
| IL239143A0 (en) | 2015-07-30 |
| AU2013356792A1 (en) | 2015-07-23 |
| CA2896673A1 (en) | 2014-06-12 |
| PL401934A1 (pl) | 2014-06-09 |
| WO2014088434A1 (en) | 2014-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ashrafizadeh et al. | (Nano) platforms in breast cancer therapy: drug/gene delivery, advanced nanocarriers and immunotherapy | |
| Zhang et al. | Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models | |
| Sun et al. | Light-activated gold–selenium core–shell nanocomposites with NIR-II photoacoustic imaging performances for heart-targeted repair | |
| Cosco et al. | In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer | |
| Zhao et al. | Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption | |
| Tian et al. | Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery | |
| Cheng et al. | Carrier‐Free Nanoassembly of Curcumin–Erlotinib Conjugate for Cancer Targeted Therapy | |
| Gorzkiewicz et al. | Dendrimers as nanocarriers for nucleoside analogues | |
| Zhang et al. | Hypoxia-triggered tumor specific glutamine inhibition for reversing cisplatin resistance of chemotherapy | |
| US10925852B2 (en) | Talc-bound compositions and uses thereof | |
| CN113631193A (zh) | 用于治疗癌症的金属螯合剂组合疗法 | |
| WO2019073296A1 (en) | LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF | |
| WO2020031136A1 (en) | Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer | |
| PL234888B1 (pl) | Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej | |
| EP4247407A1 (en) | Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer | |
| KR20190075389A (ko) | 항암제가 담지된 나노구조체를 유효성분으로 포함하는 간암 치료용 약학조성물 | |
| US20150320692A1 (en) | Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii | |
| WO2017163124A2 (en) | Medical use of poly(propylene imine) glycodendrimers | |
| PL238795B1 (pl) | Ekstrakt z grzyba poliporoidalnego, kompozycja zawierająca taki ekstrakt oraz jego zastosowanie | |
| JP6258202B2 (ja) | がん療法における標的リポソーム | |
| Dohadwala et al. | Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm | |
| Kumar et al. | Targeted delivery of paromomycin to leishmania infected macrophage by hemoglobin tagged nanocarrier | |
| Huang et al. | Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles | |
| US20180153927A1 (en) | Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III | |
| JPH08509961A (ja) | 低密度リポタンパク質および細胞毒性物質の使用 |